Eltrombopag-based combination treatment for immune thrombocytopenia
Open Access
- 4 October 2018
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 9 (10) , 309-317
Abstract
Immune thrombocytopenia (ITP) is a bleeding disorder caused by a decrease in platelet count resulting from increased destruction and insufficient production of platelets. Although impaired regulatory T-lymphocyte activity plays a critical role in platelet destruction, many other immunologic abnormalities are also likely to be involved. Importantly, patients with ITP appear to have defects in a thrombopoietin-mediated physiological mechanism that compensates for a decrease in platelet count by increasing platelet production. Thus, simultaneous treatment of multiple pathogenic pathways involved in ITP could potentially result in synergistic efficacy. While conventional treatments for ITP suppress or modulate the immune system to reduce platelet destruction, a unique class of ITP therapy, namely thrombopoietin receptor agonists (TPO-RAs), improves platelet production by activating the thrombopoietin pathway. As hypothesized, preliminary studies show that combinations of eltrombopag, an oral TPO-RA, with conventional treatments improve outcomes in both newly diagnosed and refractory patients. In this review, the clinical experience with eltrombopag-based combinations in patients with ITP is summarized and the implications of the available data are discussed.Keywords
Funding Information
- Novartis Pharmaceuticals Corporation
This publication has 49 references indexed in Scilit:
- Eltrombopag and Improved Hematopoiesis in Refractory Aplastic AnemiaNew England Journal of Medicine, 2012
- Patient-reported treatment burden of chronic immune thrombocytopenia therapiesBMC Hematology, 2012
- ITP: a historical perspectiveBritish Journal of Haematology, 2011
- Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 studyThe Lancet, 2011
- Combination of romiplostim and rituximab: effective therapy of severe immune thrombocytopeniaEuropean Journal of Haematology, 2010
- The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reportsAmerican Journal of Hematology, 2010
- The ITP syndrome: pathogenic and clinical diversityBlood, 2009
- Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working groupBlood, 2009
- Historical review: megakaryopoiesis and thrombopoiesisBlood, 2008
- Self‐reported health‐related quality of life in adults with chronic immune thrombocytopenic purpuraAmerican Journal of Hematology, 2007